Results 141 to 150 of about 23,676 (191)

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

MedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao, Wenchao Xu, Yibo Wang, Haoran Huang, Yu Su, Li Zhou, Jianzhou Liu, Junchao Guo   +7 more
wiley   +1 more source

Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
Colorectal cancer is a heterogeneous, adaptive disease shaped by population‐level risk, genomic and epigenetic alterations, tumor ecosystem evolution, and treatment pressure. This review integrates epidemiology, risk factors, signaling networks, clinical presentation, screening, molecular diagnosis, and stage‐ and biomarker‐guided management while ...
Kairui Wan, Ke Tang, Linglong Wang, Qin Tian, Mingwei Zheng, Cheng Qian, Limei Liu   +6 more
wiley   +1 more source

Applying a Pareto‐Based Efficiency Frontier to Inform Value‐Based Pricing for Gaucher Disease Therapies in Brazil

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 10, October 2026.
ABSTRACT Purpose Gaucher disease (GD) requires lifelong high‐cost treatment within the Brazilian Unified Health System (SUS). In Brazil, treatment eligibility and monitoring are defined by Clinical Protocol and Therapeutic Guidelines (PCDT), while pharmaceutical prices are regulated by the Drug Market Regulation Chamber (CMED).
Marcus Carvalho Borin, Ludmila Peres Gargano, Francisco de Assis Acurcio, Juliana Álvares‐Teodoro, Augusto Afonso Guerra Junior   +4 more
wiley   +1 more source

How to manage medullary thyroid carcinoma: current treatment strategies. [PDF]

Drugs Context
Saltiki K, Karapanou O, Michalaki M, Effraimidis G.   +3 more
europepmc   +1 more source

From Regenerative to Degenerative Niche: Multicellular Crosstalk and Population Dynamics in Skeletal Muscle Aging

Aging Cell, Volume 25, Issue 10, October 2026.
Aging transforms the skeletal muscle microenvironment from a balanced, regenerative niche into a maladaptive, degenerative state. This review highlights how disrupted multicellular crosstalk drives chronic inflammation, fibrosis, and neuromuscular dysfunction, ultimately compromising tissue repair and fueling sarcopenia.
Seongwan Kim, Min Ju Kim, Yong Ryoul Yang   +2 more
wiley   +1 more source

Targeted therapies in the management of advanced medullary thyroid cancer. [PDF]

Oncologist
Arain HA, Izhar A, Caretti R, Chen H, Vodopivec DM.   +4 more
europepmc   +1 more source

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, Volume 117, Issue 10, Page 2827-2837, October 2026.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review. [PDF]

Front Endocrinol (Lausanne)
Stanescu LS, Ioachim D, Muresan A, Smarandache R, Lider-Burciulescu SM, Gheorghiu ML, Badiu C.   +6 more
europepmc   +1 more source

Fruquintinib: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou, Arvind Dasari, Jin Li, Caly Chien, Qi Dong, Lucy Chen, Lixian Dong, Neeraj Gupta   +7 more
wiley   +1 more source

RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases. [PDF]

Cell Rep Med
Bagheri-Yarmand R, Pagnotti GM, Kidd JL, Ramirez DA, Trupti Trivedi, Guerra L, Wang Z, Cruz LM, Moehle JM, Jebaraj YS, Wan X, Song JH, Bassett RL, Lin SH, Hu MI, Sherman SI, Hofmann MC, Guise TA.   +17 more
europepmc   +1 more source